- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03772275
Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure
December 8, 2018 updated by: Sherief Abd-Elsalam
Clinical and Economical Study Evaluating the Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure
Clinical and Economic study of some new biomarkers in chronic heart failure.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The study aimed at evaluation of the clinical and economic value of some new biomarkers in chronic heart failure.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Elgharbia
-
Tanta, Elgharbia, Egypt, 35111
- Recruiting
- Sherief Abd-Elsalam
-
Contact:
- Nermin W Ishak, Msc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- NYHA-Class II-IV
Exclusion Criteria:
- Liver or renal dysfunction. --DM
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: New york Heart Association Class II-IV
New york Heart Association Class II-IV heart failure
|
New york Heart Association Class II-IV " study of markers"
Other Names:
|
|
ACTIVE_COMPARATOR: New york Heart Association Class I
New york Heart Association Class I with no heart failure
|
New york Heart Association Class I
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with elevated markers (IL17)
Time Frame: 6 months
|
Number of participants with elevated markers (IL17)
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Osama M Ibrahim, Prof, Prof of Clinical Pharmacy
- Study Director: Medhat M Eshmawy, Prof, Cardiology Department- Tanta University
- Study Chair: Nermin W Ishaq, Msc, Clinical pharmacy Department- Tanta University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2018
Primary Completion (ANTICIPATED)
October 1, 2026
Study Completion (ANTICIPATED)
October 1, 2027
Study Registration Dates
First Submitted
December 7, 2018
First Submitted That Met QC Criteria
December 8, 2018
First Posted (ACTUAL)
December 11, 2018
Study Record Updates
Last Update Posted (ACTUAL)
December 11, 2018
Last Update Submitted That Met QC Criteria
December 8, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Heart failure
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
Clinical Trials on New york Heart Association Class II-IV
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
University of SalzburgCompletedSystemic InflammationAustria
-
Texas A&M UniversityCurves InternationalCompletedDiet, Carbohydrate-Restricted
-
Assistance Publique - Hôpitaux de ParisORIXHARecruitingCardiac Arrest (CA) | Resuscitated Sudden Cardiac Death | Post Cardiac Arrest Patient Who Was Treated by Hypothermia ProtocolFrance
-
Brigham and Women's HospitalJohns Hopkins University; National Institute on Aging (NIA); Rutgers UniversityCompleted
-
Nicola GoekbugetCompletedLymphoblastic Lymphoma | Burkitt's Lymphoma | Mediastinal Neoplasms | Burkitt's Leukemia | Large Cell Anaplastic LymphomaGermany
-
National Cancer Institute (NCI)WithdrawnT Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)CompletedB Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia
-
National Cancer Institute (NCI)RecruitingB Acute Lymphoblastic LeukemiaUnited States, Puerto Rico, Australia, Canada